Article Sidebar

PDF (Tiếng Việt)
Published: 2024-05-15
Abstract Views: 136
Views PDF (Tiếng Việt): 60
DOI: https://doi.org/10.52163/yhc.v65iCD3.1132
Issue
Vol. 65 No. CĐ 3 - Bệnh viện Phổi Trung ương
Section
Articles
How to Cite
Anh, P. N. ., Việt, Đinh N. ., Việt, H. T. B. ., & Hạnh, C. X. . (2024). 35. EVALUATING THE RESULT LINE 1 OF TREATMENT NON SMALL CELL LUNG CANCER PATIENTS STAGE IV HABOR EGFR MUTATION BY OSIMERTINIB AT NATIONAL LUNG HOSPITAL FROM 2019 TO 2022. Vietnam Journal of Community Medicine, 65(CĐ 3 - Bệnh viện Phổi Trung ương). https://doi.org/10.52163/yhc.v65iCD3.1132

35. EVALUATING THE RESULT LINE 1 OF TREATMENT NON SMALL CELL LUNG CANCER PATIENTS STAGE IV HABOR EGFR MUTATION BY OSIMERTINIB AT NATIONAL LUNG HOSPITAL FROM 2019 TO 2022

Phuong Ngoc Anh1, Dinh Ngoc Viet1, Hoang Thi Bich Viet1, Can Xuan Hanh1
1 National Lung Hospital

Main Article Content

Abstract

Objectives: (1) To evaluate the rate of response and the period time of progression-free survival. (2) To evaluate side effects of Osimertinib.


Methods: Cross-sectional descriptive study 31 adenonocarcinoma lung cancer harboring EGFR mutations patients at National Lung Hospital, from December 2019 to August 2023.


Results: The mean of age is : 63,42 ± 9,36 age, the youngest is 40 and the oldest is 85 age, female/male is 1,07/1, the most common symptom is chest pain with 26 patients. The most common location metastasis is pleural with 18 patinents. EGFR mutations at exon 19 is the common than at exon 21 with rate 19/11, one patient habor T790M mutation. Overall response rate (ORR) is 70,9 % with 61,3% is partial response. The mean progression-free survival is 20,70 ± 3,32 months, median PFS is 15,67 months with minimum is 3,19 months and maximum is 44,16 months. The most common treatment accompanied is Zoledronic acid with 11 patients. Recording side effects, rash on skin is the most common with rate is 48,4 %, most of them are grade I. Side effects with increasing aspartat transaminase and alanin transaminase grade I with 8 patients (25,8%) and all side effects: No patients with grade III or grade IV.


Conclusion: Treatment by target drug as Osimertinib with patients adenocarcinoma lung cancerstage IV harboring EGFR mutations has high overall response rate : 70,9%, median progression-free survival is 15,67 months. Side effects are often mild. So with adenocarcinoma lung cancer harboring EGFR mutations, we should treatment by Osimertinib, special in old patients, who has not good performance status, can not treatment with chemotherapy.

Article Details

Keywords

Osimertinib, tagrisso lung cancer, EGFR mutations, progression-free survival, side effects, overall survival.

References

[1] Mok T.S., Wu Y.-L., Ahn M.-J. et al., Osimertinib
or Platinum–Pemetrexed in EGFR T790M–
Positive Lung Cancer. N Engl J Med, 376(7),
2017, 629–640.
[2] Soria J.-C., Ohe Y., Vansteenkiste J. et al.,
Osimertinib in Untreated EGFR-Mutated Advanced
Non–Small-Cell Lung Cancer. N Engl J Med,
378(2), 2018, 113–125.
[3] Wu Y.-L., Tsuboi M., He J. et al., Osimertinib
in Resected EGFR-Mutated Non–Small-Cell
Lung Cancer. N Engl J Med, 383(18), 2020,
1711–1723.
[4] FDA Approves Tagrisso (osimertinib) for EGFR
T790M Mutation-Positive Non-Small Cell Lung
Cancer. Drugs.com, newdrugs/fda-approves-tagrisso-osimertinibegfr-
t790m-mutation-positive-non-small-celllung-cancer-
4297.html>, accessed: 29/09/2022.
[5] FDA Approves Tagrisso (osimertinib) as FirstLine
Treatment for EGFR-Mutated Non-Small
Cell Lung Cancer. Drugs.com, drugs.com/newdrugs/fda-approves-tagrisso-osimertinib-
first-line-egfr-mutated-nonsmall-cell-lung-cancer-
4727.html>, accessed:24/09/2022.
[6] Tagrisso Approved in the US for the Adjuvant
Treatment of Patients with Early-Stage EGFR-Mutated
Non-Small Cell Lung Cancer.
Drugs.com, tagrisso-approved-us-adjuvant-patients-earlystage-
egfr-mutated-non-small-cell-lung-cancer-5411.html>,
accessed: 29/09/2022.
[7] Onoi K., Kaneko Y., Uchino J. Osimertinib in
first line setting: For Asian patients. Transl Lung
Cancer Res, 8(4), 2019.